X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.1 In other words, the correlation coefficient of the other stock
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
CTI BIOPHARMA CORP 2017 Annual Meeting TUESDAY, MAY 16, 2017
1) DIRECTOR: WITHHOLD ALL 2) Share Increase from 41 Mil to 80 Mil: AGAINST 3) EQUITY INCENTIVE PLAN: AGAINST 5) COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. AGAINST 6) EXECUTIVE COMPENSATION SHOULD OCCUR EVERY ONE, TWO OR THREE YEARS. AGAINST
James N. Lozano
How do you find the next big thing before it hits? Check out ExplosiveOTC and see the reports that detail companies on the brink of a run. www.explosiveotc.com
I'm just waiting for another huge reverse split. They killed my 2k shares a few years back. Just wait until they need more cap
Anyone can read this statement Why DCTH product sale in Europe but only 10 cent?
US FDA almost green light for DCTH
potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe, the Company's ability to successfully commercialize the CHEMOSAT/Melphalan HDS system and the potential of the CHEMOSAT/Melphalan HDS system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company's ability to satisfy the remaining requirements of the FDA's Complete Response Letter and provide the same in a timely manner, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company's ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, our ability to maintain NASDAQ listing, and uncertainties regarding the Company's ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Received an alert this am about $CTIC from http://yugestocks.com/?s=CTIC, you may want to take a look. _if people who do not understand each other understand at least thatthey do not understand each other Trading stocks day trading.
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
CTIC's recent 10-K shows that the CTIC's paclitaxel, Opaxio, has been terminated.
"Opaxio™, paclitaxel poliglumex, has been evaluated as a maintenance therapy in ovarian cancer...
In February 2017, our exclusive worldwide license for rights to paclitaxel poligumex and certain polymer technology from PG-TXL Company, L.P., or PG-TXL, was terminated as discussed below in Part I, Item 1, “Business - License Agreements and Additional Milestone Activities - PG-TXL”. No further development of paclitaxel poliglumex is planned."
Guys CVM big chance get approval, FDA only say put on hold not say failure. This April-2017 is Approval will see $5
Cancer - The Investigational Therapy Multikine® (Leukocyte Interleukin, Injection)
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
CEL-SCI's lead investigational therapy Multikine is currently being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase I and Phase II clinical trials suggest that Multikine may simulate a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. If it were to be approved for use following completion of our clinical development program, Multikine would be a different kind of therapy in the fight against cancer: one that is designed with the intent to employ our body's natural ability to fight tumors. CEL-SCI is currently conducting a large Phase III clinical study with Multikine in head and neck cancer patients with advanced disease who are treatment naïve (i.e., have received no prior treatment).
On September 26, 2016, CEL-SCI received verbal notice from the FDA that the Phase 3 clinical trial has been placed on clinical hold. On October 21, 2016, CEL-SCI issued a press release stating that, "following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the FDA. CEL-SCI is working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted." Updated information on the partial clinical hold is available on CEL-SCI's Form 8-K filed with the SEC on December 22, 2016.
The current standard of care for initial treatment of these patients according to the NCCN guidelines (published by the National Comprehensive Cancer Network) is surgery followed by radiotherapy or surgery followed by combined radiochemotherapy - depending on pathology assessment of the resected tumor following surgery. In CEL-SCI's ongoing study, Multikine is administered to patients before these other treatments are given. At the completion of CEL-SCI's clinical development program, if the results indicate that this investigational therapy met its pre-specified endpoints, a Biologics License Application will be prepared and submitted to the FDA by CEL-SCI.
Make a math PIP received 217M how much per share now? Leaking news PIP big news out in 30 min...... see you guys 1.5
PIP going shoot up to $2 + in 1 hour, PIP in earning.......
ROE is 965.4%. Looks like $CTIC did better than industry avg
Can CTI BioPharma Corp (CTIC) Continue To Outperform Its Industry?
CTI BioPharma Corp (NASDAQ:CTIC), with its ROE of 965.4 over the past 12 months, performed better than the industry, which averaged 27.48% in the same period.
Received an alert this am about $CTIC from http://monstastocks.com/?s=CTIC, you may want to take a look. Investing trading stocks. Medit's subway postulate: no matter which train you are waiting for
Monsta Stocks: Trading Stocks and Making Money
Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.
cti biopharma website under developement drugs where is paclataxel ? has it been sold or do they have a partner for it ? or can i just not find it ?
BIG DAY IS COMING TOMORROW!!!!
Judging by the relative strength index alone, which is at 62.74 on the daily chart – overall I think we will see upside in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? Im not sure about you guys but awesom-eSTOCKS has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.